What you missed at the 5th Gene Therapy for Ophthalmic Disorders Summit

Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2025 event, please get in touch at info@hansonwade.com

Leverage Gene Addition, Silencing & Editing Approaches to Revolutionize Development & Delivery of Gene Therapies to the Eye

September 10 - 12, 2024 | Boston, MA

2024 EVENT GUIDE

PARTNER

Harness Genetic Medicine for Treatment of Rare & Common Eye Diseases

Ophthalmic drug developers are unlocking the full potential of gene therapy. Crucial lessons learnt from both clinical successes and failures, coupled with recent improvements in development and delivery, means that the space is poised to capitalize on the significant potential of the eye as a target for genetic medicine approaches.

70+ industry leaders joined together at the 5th Gene Therapy for Ophthalmic Disorders Summit to uncover cutting-edge gene therapy breakthroughs:

Harness the latest developments in vector engineering to target retinal cells more effectively with higher transduction efficiency. Understand the crucial role of endpoint selection to clearly demonstrate product efficacy to the FDA & EMA.
Understand the risk-benefit profiles of different ocular administration routes including intravitreal, subretinal, and suprachoroidal delivery to choose the best option for your specific indication.
Learn from successful clinical trials as well as where trials have fallen short of expectations to take forward crucial lessons learnt on progressing a gene therapy rapidly through the clinic without compromising on safety

“We're looking forward to sharing our exciting new data in the AAV retinal gene therapy space and hearing about other emerging technologies in the field.”

Molly Johnson, Senior Director of Data Sciences, Avista Therapeutics